CLINICAL AND FUNCTIONAL CHARACTERISTICS OF RESISTANT ARTERIAL HYPERTENSION
DOI:
https://doi.org/10.11603/1811-2471.2017.v0.i1.7321Keywords:
resistant arterial hypertension, pseudo-resistant arterial hypertension, clinical and functional characteristics.Abstract
Aim of research: - to study clinical and functional characteristics of resistant and pseudo-resistant arterial hypertension. For this purpose 420 patients with essential arterial hypertension of 2-nd stage at the age from 45 to 74 who have being ill for more than 3 years with signs of resistance to hypertensive therapy were examined. All patients were divided into 2 groups: the 1-st group with resistant AH and the 2-nd group with pseudo-resistant AH. All patients' data about anamnesis, complaints, duration of being ill, existence of concomitant disease was estimated. All necessary general clinical and instrumental examinations were made according to set tasks of research: general clinical examination, ECG, EchoCG. During the research period 26,2% of patients were diagnosed true resistant AH, 73,8% - pseudo-resistant AH. Duration of pseudo-resistant AH averagely reached 8,2 ± 1,2 years, and of resistant AH - almost two times longer - 14,7 ± 2,1 years. Patients with resistant AH had more complains, higher systolic blood pressure, more frequently had comorbidity and heart rhythm and conduction disorder in comparison with patients with pseudo-resistant AH. Consequently more difficult AH progression is registered within patients with resistant AH, what creates conditions for increase of general cardiovascular risk.
References
Mancia, G., Fagard, R., & Narkiewicz, K. (2013). Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). J. Hypertens. 31, 1281-1357.
David, A. C., Daniel, J., & Stephen, T. (2008). Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 1403-1419.
Pimenta, E., & Calhoun, D.A. (2012) Resistant Hypertension: Incidence, Prevalence, and Prognosis. Circulation, 125 (13), 1594-1596.
Kearney, P., Whelton, M., & Reynolds, K. (2004). Worldwide prevalence of hypertension: a systematic review. J. of Hypertens., 22, 11-19.
Wolf-Maier, K., Cooper, R. S., & Banegas, J. R. (2003). Hypertension prevalence and blood pressure levels in European countries, Canada and the United States. JAMA. 289, 2363-2369.
Sirenko, Y.M. (2010). Hypertension and comorbidity. Donetsk: Publisher O. Zaslavsky.
Deneka, I.E., Svetankova, A.A., & Rodionov, A.V. (2016). Resistant hypertension: epidemiology and risk factors. Rational Pharmacotherapy in Cardiology, 12 (4), 459-464.
Mathers, C., Stevens, G., & Mascarenhas, M. (2009). Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization.
Obertynska, O.G. (2014). Clinical aspects of resistant hypertension. Ukr. Card. Journal, 4, 30-36.
Obertynska, O.G. (2015). Resistant hypertension: search for optimal combination therapy. Ukrainian Cardiology Journal, 6, 113-123.
Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research (2008). Hypertension, 51, 1403-1419.
